Navigation Links
Genetic and clinical factors best to predict late recurrence in estrogen receptor POS breast cancer
Date:5/2/2013

Lugano-CH, Brussels-BE, 2 May 2013 -- A new analysis has provided a comprehensive comparison of scores designed to predict which women with oestrogen-receptor positive breast cancer are at high risk of recurrence beyond five years after diagnosis, and may benefit from prolonged endocrine treatment.

The promising new findings will likely benefit the many women with oestrogen-receptor positive breast cancer whose cancer recurs more than five years after diagnosis, researchers told the 5th IMPAKT Breast Cancer Conference in Brussels, Belgium.

The IMPAKT meeting presents cutting edge, 'translational' breast cancer research that is beginning to have an impact for patients.

In oestrogen-receptor positive women, half of all recurrences of breast cancer will occur after the women finish the standard 5 years of hormonal treatment, explains lead author Dr Ivana Sestak from the Wolfson Institute of Preventive Medicine in London, UK.

"There is great interest in establishing which women are at adequate high risk of late recurrence after the initial hormonal treatment period, which is currently 5 years," Dr Sestak says.

At the meeting, researchers reported the findings of a comparison of five different scores designed to predict which women may be at increased risk of developing a late recurrence of their cancer. This is the first time that all five scores have been compared within one dataset.

Knowing which women may be at increased risk of developing a late recurrence would enable doctors to identify those women who may be good candidates for extended hormonal therapy, she says.

The ATAC trial included nearly 10,000 women who were treated with surgery followed by five years of treatment with the drugs anastrozole, tamoxifen or a combination of both. Of these 1,125 from the monotherapy arms (tamoxifen, anastrozole) were included in the transATAC study.

The five scores being compared were the:'/>"/>

Contact: Vanessa Pavinato
media@esmo.org
European Society for Medical Oncology
Source:Eurekalert

Page: 1 2 3

Related biology news :

1. Study examines effects of genetic variants for infants with neonatal abstinence syndrome
2. Genetics Society of Americas GENETICS journal highlights for May 2013
3. Europe needs genetically engineered crops, scientists say
4. Epigenetic changes shed light on biological mechanism of autism
5. Genetic circuit allows both individual freedom, collective good
6. Genetics defines a distinct liver disease
7. BGI Health forms partnership with ACIBADEM hospital on genetic disease testing
8. Genetic discovery found to influence obesity in people of African ancestry
9. Ludwig presents advancements in immunotherapy and epigenetics at the American Association for Cancer Research Annual Meeting
10. Ludwig advancements in immunotherapy and epigenetics top scientific program at AACR
11. First genetic factor in prostate cancer prognosis identified
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/5/2014)... of biology in the UTSA College of Sciences, ... selected to receive a two-year $300,00 National Science ... (EAGER). The funding supports President Obama,s BRAIN Initiative, ... new technology that will demystify complex brain processes. ... neuroscience are broken into the interactions of multiple ...
(Date:11/5/2014)... de Janeiro, Brazil -Individuals show great diversity in their ... males and females greatly differ in their perceptual evaluation ... of smell tests. , Sex differences in ... behaviors and may be connected to one,s perception of ... emotions. Thus, women,s olfactory superiority has been suggested to ...
(Date:11/4/2014)... the right time might actually help boost a species, ... in understanding animal populations, pest control and managing fish ... journal Trends in Ecology and Evolution , a ... kind of positive population effect an overall species experiences ... the size and developmental stage of the creatures that ...
Breaking Biology News(10 mins):UTSA biology professor awarded $300,000 NSF grant for brain research 2UTSA biology professor awarded $300,000 NSF grant for brain research 3The female nose always knows: Do women have more olfactory neurons? 2When less is more: Death in moderation boosts population density in nature 2
... of copying the body’s own natural "waste disposal" chemistry to ... percent of patients with urea cycle disorders --- most of ... New England Journal of Medicine summarizing a quarter century of ... phenylacetate and sodium benzoate, two chemicals the body already makes ...
... the government of The Gambia is encouraging citizens living ... to try an unproven herbal remedy. The HIV Medicine ... his unproven claims that the treatment "cures" AIDS. ... treatment to a handful of patients who had been ...
... isn’t such a good thing after all. , ... say they have confirmed what other scientists have only ... can help build stronger immune systems, and may protect ... that infants who were exposed to high levels of ...
Cached Biology News:An 'elegant' idea proves its worth 25 years later 2HIVMA opposes The Gambia's unproven AIDS remedy 2Early exposure to indoor fungus molecules may protect infants against future allergies 2
(Date:11/27/2014)... The Europe Thermal Protective Clothing market ... crucial revenue forecasts. It estimates the market to ... CAGR of 7.5%, from 2013 to 2018. , ... Protective Clothing market report for a glimpse of ... various tables and figures. , http://www.micromarketmonitor.com/market/europe-thermal-protective-clothing-5957050557.html ...
(Date:11/27/2014)... -- First articles published now available ... Elsevier , a world-leading provider of scientific, technical and ... the launch of a new journal: Extreme ... launch of Extreme Mechanics Letters is driven ... applied sciences such as micro and nanotechnologies, biotechnologies, soft ...
(Date:11/26/2014)... 2014 (PRWEB) November 26, 2014 Publicis ... network, today announced the organization has won a total ... Awards. Digitas Health LifeBrands was honored with a Silver ... PHCG agencies received eight Awards of Excellence. , ... of pharmaceutical advertising and promotion. The Awards provide a ...
(Date:11/26/2014)... November 26, 2014 The North ... segments the market for detailed analysis of the ... market to reach $616.3 million by 2018, growing ... 2018. , Browse through the TOC of the ... get an idea of the in-depth analysis and ...
Breaking Biology Technology:The Europe Thermal Protective Clothing market is estimated to grow up to $577.9 million by 2018 - Report by MicroMarket Monitor 2The Europe Thermal Protective Clothing market is estimated to grow up to $577.9 million by 2018 - Report by MicroMarket Monitor 3Elsevier Announces the Launch of a New Journal: Extreme Mechanics Letters 2Elsevier Announces the Launch of a New Journal: Extreme Mechanics Letters 3Publicis Healthcare Wins 20 Rx Club Awards 2Publicis Healthcare Wins 20 Rx Club Awards 3The North America Thermal Protective Clothing Market is estimated to grow up to $616.3 million by 2018 - Report by MicroMarket Monitor 2The North America Thermal Protective Clothing Market is estimated to grow up to $616.3 million by 2018 - Report by MicroMarket Monitor 3
... Loramyc(R) Completes Patient Enrollment Ahead ... Zensana(TM) Reformulation Complete, Resubmission on Target, WOODCLIFF ... (NYSE: PRX ) today provided an update ... pipeline,products: pafuramidine, Loramyc(R) (miconazole Lauriad(R)), and Zensana(TM),(ondansetron). These ...
... Schering-Plough,Corporation (NYSE: SGP ) will provide a ... Hassan, chairman and chief executive officer, followed,by a ... Conference on Jan. 3, 2008, at approximately 8:45 ... "unplugged" presentation., Included in Mr. Hassan,s comments ...
... Schering-Plough,Corporation (NYSE: SGP ) is scheduled to ... quarter and full year on Tuesday, Feb. 12,2008., ... conduct a conference,call to review results for the 2007 ... and CEO, and other members of management,will host the ...
Cached Biology Technology:Strativa Pharmaceuticals, the Proprietary Products Division of Par Pharmaceutical, Provides an Update on Development Status of Pafuramidine and Other in-Licensed Products 2Strativa Pharmaceuticals, the Proprietary Products Division of Par Pharmaceutical, Provides an Update on Development Status of Pafuramidine and Other in-Licensed Products 3Strativa Pharmaceuticals, the Proprietary Products Division of Par Pharmaceutical, Provides an Update on Development Status of Pafuramidine and Other in-Licensed Products 4Strativa Pharmaceuticals, the Proprietary Products Division of Par Pharmaceutical, Provides an Update on Development Status of Pafuramidine and Other in-Licensed Products 5Schering-Plough to Webcast Presentation at Morgan Stanley Pharmaceutical CEOs Unplugged Conference 2Schering-Plough Schedules Conference Call and Webcast for 2007 Fourth Quarter, Full-Year Financial Result 2